课题基金 / 基金详情

Discovery and validation of vulnerabilities and therapeutic strategies for cyclin-dependent kinase 4/6 inhibitor-resistant hormone receptor positive breast cancer

Discovery and validation of vulnerabilities and therapeutic strategies for cyclin-dependent kinase 4/6 inhibitor-resistant hormone receptor positive breast cancer
细胞周期蛋白依赖性激酶 4/6 抑制剂耐药性激素受体阳性乳腺癌的脆弱性和治疗策略的发现和验证
批准号：
435434
负责人：
Cescon David W
金额：
$65.2万
依托单位：
University Health Network (Toronto)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2020
资助国家：
加拿大
项目状态：
未结题
起止时间：
2020-10-01 至 2025-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=435434&lang=en
关键词：
Breast Cancer Cell Cycle Developmental Therapeutics Drug Development Drug Resistance Functional Genomics Preclinical Models

项目摘要

项目成果

Cescon David W的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
CDK4/6-inhibitors are a new form of targeted therapy that have been approved for the treatment of hormone receptor positive breast cancer - the most common form of this disease. These drugs, when added to standard hormone-based therapies, substantially im
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Molecular pathogenesis of BRCA1-associated and triple-negative breast cancer: mechanism of tissue specificity and identification and characterization of cooperating tumorigenic pathways.
  • 批准号：
    206486
  • 项目类别：
    Fellowship Programs
  • 资助金额：
    $1.46万
  • 财政年份：
    2009
  • 负责人：
    Cescon David W
  • 依托单位：
    University of Toronto
Molecular pathogenesis of BRCA1-associated and triple-negative breast cancer: mechanism of tissue specificity and identification and characterization of cooperating tumorigenic pathways.
  • 批准号：
    194162
  • 项目类别：
    Fellowship Programs
  • 资助金额：
    $8.74万
  • 财政年份：
    2009
  • 负责人：
    Cescon David W
  • 依托单位：
    University of Toronto
海外基金